Post-transplantation diabetes mellitus: Evaluation of treatment strategies

Clinical Transplantation

Volumn 29, Issue 5, 2015, Pages 415-424

  Haidinger, M ^a   Antlanger, M ^a   Kopecky, C ^a   Kovarik, J J ^a   Saemann M D ^a   Werzowa, J ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Dipeptidyl peptidase 4 inhibitor; Kidney transplantation; Post transplantation diabetes mellitus; Transplant associated hyperglycemia

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; INSULIN; PANCREAS ENZYME; PIOGLITAZONE; SULFONYLUREA; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL;

ADULT; ANGINA PECTORIS; ARTICLE; ATRIAL FIBRILLATION; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED STUDY; COUGHING; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EVALUATION STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GRAFT RECIPIENT; HEADACHE; HEART FAILURE; HUMAN; HYPERTRANSAMINASEMIA; HYPOGLYCEMIA; HYPONATREMIA; KIDNEY TRANSPLANTATION; LEUKOCYTOSIS; LEUKOPENIA; LIFESTYLE MODIFICATION; MALE; ORAL GLUCOSE TOLERANCE TEST; OUTPATIENT DEPARTMENT; PANCREATITIS; PNEUMONIA; POST TRANSPLANTATION DIABETES MELLITUS; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; ADVERSE EFFECTS; ANALYSIS; GLOMERULUS FILTRATION RATE; GLUCOSE TOLERANCE TEST; GRAFT REJECTION; GRAFT SURVIVAL; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED; PROGNOSIS; RISK FACTOR;

BLOOD GLUCOSE; DIABETES MELLITUS; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLUCOSE TOLERANCE TEST; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84928740547     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12541     Document Type: Article

References (37)

1. Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2012: 8: 34.
2. Valderhaug TG, Hjelmesaeth J, Hartmann A et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011: 54: 1341.
3. Chakkera HA, Knowler WC, Devarapalli Y et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010: 5: 1669.
4. Burroughs TE, Swindle J, Takemoto S et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007: 83: 1027.
5. Hecking M, Werzowa J, Haidinger M et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant 2013: 28: 550.
6. Davidson JA, Wilkinson A. New-Onset Diabetes After Transplantation 2003 International Consensus Guidelines: an endocrinologist's view. Diabetes Care 2004: 27: 805.
7. Hecking M, Kainz A, Werzowa J et al. Glucose metabolism after renal transplantation. Diabetes Care 2013: 36: 2763.
8. Zelle DM, Corpeleijn E, Deinum J et al. Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care 2013: 36: 1926.
9. Sharif A, de Vries AP, Porrini E, Hecking M, Saemann M. Clinical trials for treatment of NODAT: time to collaborate. Transplantation 2012: 94: e23; author reply e4-5.
10. Hecking M, Haidinger M, Doller D et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012: 23: 739.
11. Werzowa J, Hecking M, Haidinger M et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013: 95: 456.
12. Haidinger M, Werzowa J, Hecking M et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial. Am J Transplant 2014: 14: 115.
13. Strom Halden TA, Asberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol Dial Transplant 2014: 29: 926.
14. Boerner BP, Miles CD, Shivaswamy V. Efficacy and safety of sitagliptin for the treatment of new-onset diabetes after renal transplantation. Int J Endocrinol 2014: 2014: 617638.
15. Sharif A. Metformin for patients with diabetes and concomitant renal restrictions-is there an evidence base? QJM 2013: 106: 291.
16. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis. Oncologist 2013: 18: 148.
17. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012: 184: E675.
18. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003: 26: 2983.
19. Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 2007: 41: 2014.
20. Saemann MD, Krebs M. Thiazolidinediones in the treatment of patients with post-transplant-hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - a new therapeutic option? Wien Klin Wochenschr 2010: 122: 198.
21. Shin MS, Yu JH, Jung CH et al. The duration of sulfonylurea treatment is associated with beta-cell dysfunction in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2012: 14: 1033.
22. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005: 90: 501.
23. Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000: 35: 500.
24. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008: CD006739.
25. Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011: 92: e56.
26. Valdes S, Botas P, Delgado E, Alvarez F, Cadorniga FD. Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias Study Metabolism 2008: 57: 399.
27. Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003: 17: 305.
28. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation 2006: 82: 1667.
29. Delgado P, Diaz JM, Silva I et al. Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study. Clin J Am Soc Nephrol 2008: 3: 808.
30. Valderhaug TG, Jenssen T, Hartmann A et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009: 88: 429.
31. Shabir S, Jham S, Harper L, Ball S, Borrows R, Sharif A. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. Transpl Int 2013: 26: 315.
32. Valderhaug TG, Hjelmesaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. Transplantation 2012: 94: 714.
33. Russo E, Penno G, Del Prato S. Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin. Diabetes Metab Syndr Obes 2013: 6: 161.
34. Hamamoto S, Kanda Y, Shimoda M et al. Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab 2013: 15: 153.
35. Omar BA, Vikman J, Winzell MS et al. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia 2013: 56: 1752.
36. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004: 17: 365.
37. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011: 141: 150.